Participants who took tirzepatide (Zepbound) dropped an average of 50 pounds over 72 weeks. Those who took semaglutide ...

Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Q2 2025 Results Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Also in March 2025, Wave announced that the company met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...